Startseite The crystal structure of N-cyclopentyl-3-hydroxy-4-methoxybenzamide, C13H17NO3
Artikel Open Access

The crystal structure of N-cyclopentyl-3-hydroxy-4-methoxybenzamide, C13H17NO3

  • Jingxiao Zhang ORCID logo EMAIL logo , Shubin Guo , Yongnan Guo und Yanliang Yang
Veröffentlicht/Copyright: 12. April 2022

Abstract

C13H17NO3, monoclinic, Cc (no. 9), a = 11.6502(8) Å, b = 13.8752(8) Å, c = 7.9644(5) Å, β = 106.051(2)°, V = 1237.25(14) Å3, Z = 4, R gt (F) = 0.0427, wR ref(F 2) = 0.1023, T = 170 K.

CCDC no.: 2158291

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colorless block
Size: 0.28 × 0.15 × 0.12 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.09 mm−1
Diffractometer, scan mode: D8 VENTURE, φ and ω
θ max, completeness: 26.4°, 98%
N(hkl)measured, N(hkl)unique, R int: 5924, 2141, 0.045
Criterion for I obs, N(hkl)gt: I obs > 2 σ(I obs), 1747
N(param)refined: 157
Programs: Bruker [1], Olex2 [2], SHELX [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
C1 0.7121 (3) 0.5779 (2) 0.8326 (4) 0.0368 (9)
H1A 0.708766 0.551263 0.947884 0.044*
C2 0.8348 (3) 0.5581 (3) 0.8098 (5) 0.0426 (9)
H2A 0.836531 0.570422 0.688133 0.051*
H2B 0.859790 0.490786 0.841437 0.051*
C3 0.9146 (4) 0.6297 (3) 0.9369 (5) 0.0503 (11)
H3A 0.942702 0.601663 1.055539 0.060*
H3B 0.984837 0.647802 0.896745 0.060*
C4 0.8349 (4) 0.7172 (3) 0.9366 (6) 0.0570 (12)
H4A 0.839466 0.736907 1.057803 0.068*
H4B 0.860384 0.772170 0.876208 0.068*
C5 0.7080 (4) 0.6871 (3) 0.8407 (6) 0.0526 (11)
H5A 0.651019 0.708429 0.905182 0.063*
H5B 0.683580 0.715006 0.721744 0.063*
C6 0.5604 (3) 0.4543 (2) 0.7103 (4) 0.0301 (8)
C7 0.4537 (3) 0.4270 (2) 0.5658 (4) 0.0286 (8)
C8 0.4214 (3) 0.3299 (2) 0.5526 (4) 0.0337 (8)
H8 0.468580 0.284715 0.631995 0.040*
C9 0.3223 (3) 0.2986 (2) 0.4263 (5) 0.0339 (8)
C10 0.2517 (3) 0.3656 (2) 0.3104 (4) 0.0319 (8)
C11 0.2831 (3) 0.4617 (2) 0.3241 (4) 0.0321 (8)
H11 0.235661 0.507130 0.245544 0.039*
C12 0.3835 (3) 0.4925 (2) 0.4517 (4) 0.0311 (8)
H12 0.404043 0.558965 0.460637 0.037*
C13 0.0842 (3) 0.3921 (3) 0.0620 (5) 0.0464 (10)
H13A 0.018946 0.356452 −0.017842 0.070*
H13B 0.134297 0.421863 −0.004277 0.070*
H13C 0.050918 0.442449 0.121220 0.070*
N1 0.6129 (3) 0.5381 (2) 0.6962 (3) 0.0357 (7)
H1 0.586283 0.571266 0.599029 0.043*
O1 0.5970 (2) 0.40001 (16) 0.8395 (3) 0.0357 (6)
O2 0.2991 (2) 0.20202 (16) 0.4160 (4) 0.0509 (8)
H2 0.225880 0.192950 0.370114 0.076*
O3 0.1550 (2) 0.32725 (16) 0.1895 (3) 0.0384 (6)

Source of material

A mixture of 10 mmol 3-hydroxy-4-methoxybenzoic acid, 10.4 mmol cyclopentylamine, and 20 mmol N,N-diisopropylethylamine (DIEA) were dissolved in 20 mL DMF. Then, 10.4 mmol of 2-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) was added to the above solution. After 5 h stirring, the reaction was complete as monitored by Thin Layer Chromatography. Hundred milliliters of brine was added to the mixture, and the product was extracted with ethyl acetate (3 times with 500 mL). This product was washed with 5% citric acid, 5% NaHCO3, and H2O respectively. The mixture was dried over MgSO4, filtered, and concentrated under vacuum. The crystals were achieved through recrystallization in ethyl acetate, and dried at room temperature for seven days.

Experimental details

All H atoms bonded to their parent C atoms were treated as riding atoms in their geometrically idealized positions, with d(C–H) = 0.95 Å and U iso = 1.2 U eq.

Comment

Benzamide derivatives were studied to exhibit several biological properties, like antiviral [5], antipsychotic [6], anti-cancer [7], anti-oxidant [8], anti-inflammatory [9], anti-Alzheimer, anti-fatigue [10], and antidiabetic effects [11]. For example, several sulfamoylbenzamides and benzamide derivatives were verified to exhibit antiviral effects via significantly reducing intracellular HBV DNA in the cytoplasm [5, 12]. Some nitro benzamide analogs could significantly inhibit the expression of cyclooxygenase-2, interleukin-1β and tumor necrosis factor, and exhibited anti-inflammatory activities [13]. Additionally, some benzamide derivatives, like metoclopramide, exhibited anti-emetic properties through blocking dopaminergic and serotonergic receptors [6], and were also used for the treatment of gastroesophageal reflux disease in infants [14].

The molecular structure of the title compound is displayed in figure. All bond lengths and angles are normal, and agree with structural reports of 4-methoxybenzamide derivatives [15], [16], [17]. The methoxy-substituted benzene [C7–C12] forms a dihedral angle of 22.9° with the amide group [–N1–C6=O1–]. The cyclopentyl ring adopts a conformation between envelope and half-chair. The hydroxyl group donates its H atom to O1, which acts as acceptor in the strong intermolecular hydrogen bond (O2–H2···O1, 1.943(3) Å).


Corresponding author: Jingxiao Zhang, College of Food and Medicine, Luoyang Normal University, Luoyang, China, E-mail:

Funding source: National Natural Science Foundation of China http://dx.doi.org/10.13039/501100001809

Award Identifier / Grant number: 21902071

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was financially supported by the National Natural Science Foundation of China (21902071).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SMART APEX-II CCD; Bruker AXS Inc.: Madison, WI, USA, 2006.Suche in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

4. Sheldrick, G. M. SHELXTL – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Suche in Google Scholar PubMed PubMed Central

5. Wu, S., Zhao, Q., Zhang, P., Kulp, J., Hu, L., Hwang, N., Zhang, J., Block, T. M., Xu, X., Du, Y., Chang, J., Guo, J. T. Discovery and mechanistic study of benzamide derivatives that modulate hepatitis B virus capsid assembly. J. Virol. 2017, 91, Art. no. e00519-17; https://doi.org/10.1128/JVI.00519-17.Suche in Google Scholar PubMed PubMed Central

6. Oltmanns, D., Eisenhut, M., Mier, W., Haberkorn, U. Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors. Curr. Med. Chem. 2009, 16, 2086–2094; https://doi.org/10.2174/092986709788612684.Suche in Google Scholar PubMed

7. Mahdavi, M., Lavi, M. M., Yekta, R., Moosavi, M. A., Nobarani, M., Balalaei, S., Arami, S., Rashidi, M. R. Evaluation of the cytotoxic, apoptosis inducing activity and molecular docking of spiroquinazolinone benzamide derivatives in MCF-7 breast cancer cells. Chem. Biol. Interact. 2016, 260, 232–242; https://doi.org/10.1016/j.cbi.2016.10.004.Suche in Google Scholar PubMed

8. Perin, N., Roškarić, P., Sović, I., Boček, I., Starčević, K., Hranjec, M., Vianello, R. Amino-substituted benzamide derivatives as promising antioxidant agents: a combined experimental and computational study. Chem. Res. Toxicol. 2018, 31, 974–984; https://doi.org/10.1021/acs.chemrestox.8b00175.Suche in Google Scholar PubMed

9. Hussain, A. A., Abdulla, M. M., Amr, A. E.-G. E., Al-Omar, M. A., Shalaby, A. F. A. Anti-inflammatory activities of some newly synthesized pyridinyl- and indazolyl benzamide derivatives. Russ. J. Bioorg. Chem. 2015, 41, 87–96; https://doi.org/10.1134/s106816201405015x.Suche in Google Scholar

10. Taj, M., Tirmizi, S., Raheel, A., Ali, H. M., Qureshi, S., Alshatir, H. Benzamide derivatives as potential candidates for anti-Alzheimer, anti-fatigue, anti-urease and anti-oxidant activity. J. Chil. Chem. Soc. 2017, 62, 3342–3344; https://doi.org/10.4067/s0717-97072017000100007.Suche in Google Scholar

11. Singh, R., Lather, V., Pandita, D., Judge, V., Arumugam, K. N., Singh Grewal, A. Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators. Lett. Drug Des. Discov. 2017, 14, 540–553; https://doi.org/10.2174/1570180813666160819125342.Suche in Google Scholar

12. Campagna, M. R., Liu, F., Mao, R., Mills, C., Cai, D., Guo, F., Zhao, X., Ye, H., Cuconati, A., Guo, H., Chang, J., Xu, X., Block, T. M., Guo, J.-T. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J. Virol. 2013, 87, 6931–6942; https://doi.org/10.1128/jvi.00582-13.Suche in Google Scholar PubMed PubMed Central

13. Tumer, T. B., Onder, F. C., Ipek, H., Gungor, T., Savranoglu, S., Tok, T. T., Celik, A., Ay, M. Biological evaluation and molecular docking studies of nitro benzamide derivatives with respect to in vitro anti-inflammatory activity. Int. Immunopharm. 2017, 43, 129–139; https://doi.org/10.1016/j.intimp.2016.12.009.Suche in Google Scholar PubMed

14. Hibbs, A. M., Lorch, S. A. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006, 118, 746–752; https://doi.org/10.1542/peds.2005-2664.Suche in Google Scholar PubMed

15. Zhang, J., Zhao, X., Cai, C. The crystal structure of N-cyclohexyl-3-hydroxy-4-methoxybenzamide C14H19NO3. Z. Kristallogr. N. Cryst. Struct. 2022, 237, 543–545.10.1515/ncrs-2022-0066Suche in Google Scholar

16. Kant, R., Sahi, S., Gupta, V. K., Kapoor, K., Paul, S. N-(4-Chlorophenyl)-4-methoxybenzamide. Acta Crystallogr. 2012, E68, o3077; https://doi.org/10.1107/s1600536812041384.Suche in Google Scholar PubMed PubMed Central

17. Li, H. L., Zeng, H. S., Kang, S. S., Wang, H. B. 4-Methoxybenzamide oxime. Acta Crystallogr. 2007, E63, o4763; https://doi.org/10.1107/s1600536807059429.Suche in Google Scholar

Received: 2022-02-14
Accepted: 2022-03-14
Published Online: 2022-04-12
Published in Print: 2022-08-26

© 2022 Jingxiao Zhang et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of N-((3s,5s,7s)-adamantan-1-yl)-2-(3-benzoylphenyl)propanamide, C26H29NO2
  4. The crystal structure of bis(μ2-5-chloro-2-oxido-N-(1-oxidopropylidene)benzohydrazonato-κ5 N,O,O′:N′,O′′)-octakis(pyridine-κ1 N)trinickel(II) C60H56Cl2N12Ni3O6
  5. The crystal structure of 3-(4-chlorophenyl)-1,5-di-p-tolylpentane-1,5-dione, C25H23ClO2
  6. The crystal structure of 2,4,4-triphenyl-4H-benzo[b][1,4]oxaphosphinin-4-ium bromide – dichloromethane (1/1), C27H22BrCl2OP
  7. The crystal structure of 2-(3,6-di-tert-butyl-1,8-diiodo-9H-carbazol-9-yl)acetonitrile, C22H24I2N2
  8. Crystal structure of 3-phenylpropyl 2-(6-methoxynaphthalen-2-yl)propanoate, C23H24O3
  9. The crystal structure of (4-fluorophenyl)(5-(hydroxymethyl)furan-2-yl)methanol, C12H11FO3
  10. Crystal structure of the dihydrate of tetraethylammonium 1,3,5-thiadiazole-5-amido-2-carbamate, C11H27N5O4S
  11. Crystal structure of (Z)-4-[(p-tolylamino)(furan-2-yl)methylene]-3-phenyl-1-1-p-tolyl-1H-phenyl-1H-pyrazol-5(4H)-one, C28H23N3O2
  12. The crystal structure of (E)-3-(2-chlorophenyl)-1-ferrocenylprop-2-en-1-one, C19H15ClFeO
  13. The pseudosymmetric crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium hexachloridostannate(IV), C10H16N2SnCl6
  14. Crystal structure of (2-(1-hydroxyheptyl)octahydro-8aH-chromene-5,8,8a-triol), C16H30O5
  15. The crystal structure of N-cyclohexyl-3-hydroxy-4-methoxybenzamide, C14H19NO3
  16. Crystal structure of 1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol from Arundina graminifolia, C22H20O4
  17. The crystal structure of N-cyclopentyl-3-hydroxy-4-methoxybenzamide, C13H17NO3
  18. The crystal structure of 2,5,5-triphenyl-3,5-dihydro-4H-imidazol-4-one, C21H16N2O
  19. Crystal structure of 1H-1,2,3-Triazolo[4,5-b]-pyridin-4-ium nitrate, C5H5N5O3
  20. Crystal structure of (Z)-4-(((4-bromophenyl)amino)(furan-2-yl)methylene)-2,5-diphenyl-2,4-dihydro-3H-pyrazol-3-one, C26H18BrN3O2
  21. Crystal structure of 2-(4-methoxyphenyl)-3-methyl-1,8-naphthyridine, C16H14N2O
  22. The crystal structure of 3-([1,1′-biphenyl]-2-yl)-1,2-diphenylbenzo[b]phosphole-1-oxide, C32H23OP
  23. The crystal structure of ammonium (E)-4-((4-carboxyphenyl)diazenyl)benzoate, C14H13N3O4
  24. Crystal structure of bis(5-amino-1,2,4-triazol-4-ium-3-yl)methane sulfate, C5H10N8O4S
  25. The crystal structure of phenantroline-κ2 N,N′-bis(6-phenylpyridine-2-carboxylato-κ2 N,O)copper(II), C36H24N4O4Cu
  26. The crystal structure of tris(6-methylpyridin-2-yl)phosphine oxide, C18H18N3OP
  27. The crystal structure of N-(2′-hydroxymethyl-5′-phenyl-3′,4′-dihydro-[1,1′:3′,1″-terphenyl]- 1′(2′H)-yl)-P,P-diphenylphosphinic amide, C37H34NO2P
  28. Crystal structure of (E)-4-(6-(4-(2-(pyridin-4-yl)vinyl)phenoxy)pyrimidin-4-yl)morpholine, C21H20N4O2
  29. Crystal structure of 5-(adamantan-1-yl)-3-[(4-trifluoromethylanilino)methyl]-2,3-dihydro-1,3,4-oxadiazole-2-thione, C20H22F3N3OS
  30. Crystal structure of 2,2-dichloro-1-(4-chloro-1H-indol-1-yl)ethan-1-one, C10H6Cl3NO
  31. The crystal structure of 4-(((3-bromo-5-(trifluoromethyl)pyridin-2-yl)oxy)methyl)benzonitrile, C28H16Br2F6N4O2
  32. The crystal structure of 1H-benzimidazole-2-carboxamide, C8H7N3O
  33. The crystal structure of Histidinium hydrogensquarate, C10H11N3O6
  34. The crystal structure of 3-amino-5-carboxypyridin-1-ium iodide, C6H7IN2O2
  35. Crystal structure of (E)-amino(2-(3-ethoxy-4-hydroxybenzylidene)hydrazineyl)methaniminium nitrate hemihydrate C10H16N5O5.5
  36. Crystal structure of 1,2-bis(4,5-dinitro-1H-imidazol-1-yl)ethane, C8H6N8O8
  37. The crystal structure of diaqua-bis(pyrazolo[1,5-a]pyrimidine-3-carboxylato-κ2N,O)manganese(II), C14H12N6O6Mn
  38. The crystal structure of catena-poly[aqua-2,2′bipyridine-κ2N,N′-(μ2-5-ethoxyisophthalato-κ 4O,O:Oʺ,O′ʺ)cadmium(II)] monohydrate, C20H20CdN2O7
  39. The crystal structure of (1S,3R)-1-(4-isopropylphenyl)-3-(methoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-iumchloride monohydrate, C22H27ClN2O3
  40. Crystal structure of 1-isopropyl-3-(prop-1-en-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, C11H15N5
  41. The crystal structure of (2,2′-bipyridine-κ2N,N′)- bis(6-phenylpyridine-2-carboxylate-κ2N,O)manganese(II)] monohydrate, C34H26N4O5Mn
  42. Crystal structure of the cocrystal 1,3,5,7-tetranitro-1,3,5,7-tetrazoctane ─ 2,3-dihydroindole (1/1), C12H17N9O8
  43. Crystal structure of 3-acetyl-6-hydroxy-2H-chromen-2-one monohydrate, C11H10O5
  44. Crystal structure of 6,9-diamino-2-ethoxyacridinium 3,5-dinitrobenozate — dimethylsulfoxide — water (1/1/1), C24H27N5O9S
  45. The crystal structure of 4,4′-bipyridinium bis-(2-hydroxy-3-methoxybenzoate), 2(C8H7.68O4)·C10H8.64N2
  46. Crystal structure of (Z)-4-(((4-fluorophenyl)amino)(furan-2-yl)methylene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
  47. The crystal structure of bis(4-chloro-2-(((2-chloroethyl)imino)methyl)phenolato-κ2N,O)-oxidovanadium(IV), C18H16Cl4N2O3V
  48. The crystal structure of 17-(bromoethynyl)-17-hydroxy-10, 13-dimethyl- 1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one, C21H27BrO2
  49. The crystal structure of 4-((6-fluoropyridin-2-yloxy)methyl)benzonitrile, C13H9FN2O
  50. Crystal structure of (Z)-2-(1-bromo-2-phenylvinyl)-5-ethyl-2-methyl-1,3-dioxane-5-carboxylic acid, C15H17Br1O4
  51. Crystal structure of catena-poly[tribenzyl-κ1C-(μ2-6-oxidopyridin-1-ium-3-carboxylato-κ2O:O’)tin(IV)-dichloromethane-methanol (1/1/1), C29H31Cl2NO4Sn
  52. Crystal structure of bis{2-(tert-butyl)-6-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O}zinc(II), C40H46N4O4Zn
  53. Crystal structure of diaqua-bis(μ2-2-carboxy-3,4,5,6-tetrafluorobenzoato-κ2O:O′)-bis(phenanthroline-κ2N,N′)-bis(μ2-3,4,5,6-tetrafluorophthalato-κ3O:O,O′)dieuropium(III) – phenanthroline (1/2), C40H19EuF8N4O9
  54. The crystal structure of diaqua-bis(6-phenylpyridine-2-carboxylato-κ2N,O) manganese(II) — water — dimethylformamide (1/2/1), C27H31N3O9Mn
  55. The crystal structure of bis(pyrazolo[1,5-a]pyrimidine-3-carboxylato-κ2N,O)-copper(ii), C14H8N6O4Cu
  56. Crystal structure of poly[(μ2-1-(1-imidazolyl)-4-(imidazol-1-ylmethyl)benzene-κ2N:N′)-(μ3-pyridazine-4,5-dicarboxylate-κ3O:O′:N)]copper(II) hydrate, C19H16CuN6O5
  57. Crystal structure of acrinidinium tetrafluorohydrogenphthalate, C21H11F4NO4
  58. Crystal structure of 2-(1H-pyrazol-3-yl-κN)pyridine-κN-bis(2-(2,4-difluorophenyl)pyridinato-κ2C,N)iridium(III) sesquihydrate, C30H18F4IrN5·1.5[H2O]
  59. Crystal structure of 2-(2-hydroxy-5-nitrophenyl)-5-methyl-1,3-dioxane-5-carboxylic acid, C12H13N1O7
  60. The crystal structure of 1,2-bis(pyridinium-4-yl)ethane diperchlorate, C12H14N2·2ClO4 – a second polymorph
  61. The crystal structure of [(1,10-phenantroline-κ2N,N′)-bis(6-phenylpyridine-2-carboxylato-κ2N,O)manganese(II)] monohydrate, C36H26N4O5Mn
  62. Crystal structure of 1,2-bis(2,2,3,3,5,5,5-heptamethyl-1,1,4,4- tetrakis(trimethylsilyl)pentasilan-1-yl)ditellane, C38H114Si18Te2
  63. Crystal structure of 1,2-bis(2,4-dinitro-1H-imidazol-1-yl)ethane – dimethylformamide (1/1), C11H13N9O9
  64. Crystal structure of (Z)-3-((tert-butylamino) methylene)-2-(2-hydroxynaphthalen-1-yl) chroman-4-one, C24H23NO3
  65. Synthesis and crystal structure of (E)-1-(4-(((E)-3-(tert-butyl)-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-ethyl oxime, C21H26N2O2
  66. Crystal structure of the double salt bis(5-amino-1,2,4-triazol-4-ium-3-yl)methane hydrogen oxalate hemioxalate, C8H11N8O6
  67. Hydrothermal synthesis and crystal structure of catena-poly[diaqua-bis(μ2-4-[(4-pyridinylmethyl)amino]benzoato-κ2N:O)cobalt(II)]–1,2bi(4-pyridyl)ethene–water (1/1/1), C50H50N8O8Co
  68. Crystal structure of 3-(3-bromophenyl)-1′,3′-dimethyl-2′H,3H,4H-spiro[furo[3, 2-c]chromene-2,5′-pyrimidine]-2′,4,4′,6′(1′H,3′H) tetraone, C22H15BrN2O6
  69. The crystal structure of poly[aqua-(μ2-4,4′- bis(imidazolyl)biphenyl-κ2N:N′)-(μ2-3-nitrobenzene-1,2-dicarboxylato-κ2O:O′)]copper (II) hydrate, C26H21N5O8Cu
  70. The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C36H52F2N8O14
  71. Synthesis and crystal structure of poly[aqua(μ4-(1R,2S,4R)-4-hydroxy-1-((7-hydroxy-3-(4-hydroxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)pyrrolidin-1-ium-2-carboxylate-κ4O:O′:O″:O‴)sodium(I)] monohydrate, C21H22NNaO12S
  72. Crystal structure of chlorido-(η6-toluene)(2,2′-bipyridine-κ2N,N′)ruthenium(II) hexafluorophosphate, C17H16ClN2RuPF6
  73. The crystal structure of (R)-6-hydroxy-8-methoxy-3-methylisochroman-1-one, C11H12O4
  74. Crystal structure of catena-poly[(5,5,7,12,12,14-hexamethyl -1,4,8,11-tetraazacyclotetradecane- κ4N,N′,Nʺ,N‴)nickel(II)-(μ2-perchlorato-κ2O:O′)] 3,5-dicarboxybenzoate – methanol (1/2), C27H49ClN4NiO12
  75. The crystal structure of 4-(chloromethyl)benzonitrile, C8H6ClN
  76. The crystal structure of dimethylammonium 8-[(7,9-dioxo-6,10-dioxaspiro[4.5]decan-8-ylidene)methyl]-9-oxo-6,10-dioxaspiro[4.5]dec-7-en-7-olate, C19H25NO8
  77. Crystal structure of (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-((1-acetyl-5-bromo-4-chloro-1H-indol-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate hemihydrate C24H25BrClNO11
  78. The crystal structure of the co-crystal tetrakis[2-(tris(4-methoxyphenyl)stannyl)ethyl]silane – tetrahydrofuran – toluene – tetrahydrofurane (1/1/1), C103H116O13SiSn4
  79. Crystal structure of methyl 3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate, C16H13NO4
  80. Crystal structure of ethyl (Z)-3-amino-2-cyano-3-(2-oxo-2H-chromen-3-yl)acrylate, C15H12N2O4
  81. Crystal structure of methyl 2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetate, C15H11NO4
  82. Crystal structure of catena-poly[diaqua-bis(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2N:N′)cobalt(II)] tetrafluoroterephthalate, C26H28N8O6F4Co
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0070/html
Button zum nach oben scrollen